SynthesisInternational journal of cardiology2022
Myocarditis after RNA-based vaccines for coronavirus.
Synthesis in International journal of cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- An overview and single-arm meta-analysis of immune-mediated adverse events following COVID-19 vaccination.Frontiers in pharmacology · 2024Pooled it
- Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis.BMJ open · 2023Pooled it
- Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults: A Systematic Review and Meta-analysis.JAMA pediatrics · 2023Pooled it
- Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus · 2025Review
- Meta-analysis and Meta-regression for Uncertain Areas and the Estimation of Possible Benefit of Future Therapies.European cardiology · 2025Review
- Innate and adaptive immunity in acute myocarditis.International journal of cardiology · 2024Review
- Article
- Cardiovascular complications in vascular connective tissue disorders after COVID-19 infection and vaccination.PloS one · 2024Article
- An Extensive Review on Imaging Diagnosis Methods in Takotsubo Syndrome.Reviews in cardiovascular medicine · 2023Review
- Article
- Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management.Revista espanola de cardiologia (English ed.) · 2023Article
- [Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management].Revista espanola de cardiologia · 2023Article
- Review
- Tachycardia following Pfizer-BioNTech COVID-19 vaccine.Enfermedades infecciosas y microbiologia clinica (English ed.) · 2023Article
- Cardiac Safety of mRNA-Based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis.Pathogens (Basel, Switzerland) · 2022Article
- Incidence of Myocarditis after Messenger RNA Vaccine for COVID-19 in Young Male Recipients.The American journal of cardiology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest.
methodsWe performed an intention-to-treat meta-analysis, following the PRISMA statement. After a systematic search, without language restriction, 9 publications were selected. Two were excluded (one was only in subjects with age 12-17 and other might had included subjects from a larger publication). We followed the PRISMA guidelines for abstracting data and assessing data quality and validity. Data was verified by 2 investigators.
resultsWe analyzed 17,704,413 subjects, from 7 studies, that included 627 cases of confirmed myocarditis). The incidence of myocarditis was 0.0035% (95% CI 0.0034-0.0035). Mean incidence rate was 10.69 per 100.000 persons-year. Cases reported from Israel represented 45.14% from total (283 out of the 627). Only 1 case of fatal myocarditis or death was reported. There was significant heterogeneity between results. The meta-regression analysis excluded mean age, region, number of cases or number of people included as sources of heterogeneity. No small-study effect was observed (p = 0.19). CONCLUSIONS AND RELEVANCE: Myocarditis incidence after RNA vaccines is very rare (0.0035%) and has a very favorable clinical course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.